FDA denies making a promise on opioids

Share this article:
Rep. Harold Rogers
Rep. Harold Rogers

Contrary to a claim by a Kentucky Republican congressman that he was assured by FDA that it would not approve new opioids unless they had abuse-deterrent formulations, the agency says it never made such a commitment. Rep. Harold Rogers made his claim in commenting to the New York Times on the agency's Oct. 25 approval of Zogenix's single-ingredient hydrocodone bitartrate analgesic Zohydro ER, the day after it said it had agreed to support regulatory restrictions on combination hydrocodone products.

The approval had “dismayed” public health advocates, the newspaper reported, noting that an advisory panel last December had voted 11-2 against it because it could lead to the same type of abuse and addiction as OxyContin before it was reformulated to deter abuse.

FDA Press Office spokesperson Morgan Liscinski said the agency's Office of Legislation “has reached out to Rep. Rogers' office regarding his comments.”

In an earlier statement on the controversy, FDA said it was “committed to ongoing efforts to reduce opioid misuse and abuse while seeking to ensure that patients in pain continue to have appropriate access to these products. We consider the development of opioid analgesics with abuse-deterrent properties to be a public health priority and are actively supporting product development in this area, but the science is still in its early stages and abuse-deterrent formulations are not available for most ER/LA analgesics. Accordingly, the FDA does not believe it is feasible at this time to require that all new solid oral dosage form opioids have abuse-deterrent properties.”

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.